Literature DB >> 26545765

[Acute toxicity after hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer].

Frank Lohr1, Michael Ehmann2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26545765     DOI： 10.1007/s00066-015-0924-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Authors:  David Dearnaley; Isabel Syndikus; Georges Sumo; Margaret Bidmead; David Bloomfield; Catharine Clark; Annie Gao; Shama Hassan; Alan Horwich; Robert Huddart; Vincent Khoo; Peter Kirkbride; Helen Mayles; Philip Mayles; Olivia Naismith; Chris Parker; Helen Patterson; Martin Russell; Christopher Scrase; Chris South; John Staffurth; Emma Hall
Journal:  Lancet Oncol       Date:  2011-12-12       Impact factor: 41.316

2.  Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer.

Authors:  Stefano Arcangeli; Lidia Strigari; Sara Gomellini; Biancamaria Saracino; Maria Grazia Petrongari; Paola Pinnarò; Valentina Pinzi; Giorgio Arcangeli
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-24       Impact factor: 7.038

3.  Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.

Authors:  Himu Lukka; Charles Hayter; Jim A Julian; Padraig Warde; W James Morris; Mary Gospodarowicz; Mark Levine; Jinka Sathya; Richard Choo; Hugh Prichard; Michael Brundage; Winkle Kwan
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Dose-Escalated Irradiation and Overall Survival in Men With Nonmetastatic Prostate Cancer.

Authors:  Anusha Kalbasi; Jiaqi Li; Abigail Berman; Samuel Swisher-McClure; Marc Smaldone; Robert G Uzzo; Dylan S Small; Nandita Mitra; Justin E Bekelman
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

Review 5.  A systematic review of hypofractionation for primary management of prostate cancer.

Authors:  Bridget F Koontz; Alberto Bossi; Cesare Cozzarini; Thomas Wiegel; Anthony D'Amico
Journal:  Eur Urol       Date:  2014-09-22       Impact factor: 20.096

6.  Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Authors:  Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

7.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

Authors:  Christopher R King; Debra Freeman; Irving Kaplan; Donald Fuller; Giampaolo Bolzicco; Sean Collins; Robert Meier; Jason Wang; Patrick Kupelian; Michael Steinberg; Alan Katz
Journal:  Radiother Oncol       Date:  2013-09-20       Impact factor: 6.280

8.  Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival.

Authors:  Wilma D Heemsbergen; Abrahim Al-Mamgani; Annerie Slot; Michel F H Dielwart; Joos V Lebesque
Journal:  Radiother Oncol       Date:  2013-11-15       Impact factor: 6.280

9.  Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.

Authors:  David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes
Journal:  Lancet Oncol       Date:  2014-02-26       Impact factor: 41.316

Review 10.  Hypofractionated radiotherapy for prostate cancer.

Authors:  Nina-Sophie Hegemann; Matthias Guckenberger; Claus Belka; Ute Ganswindt; Farkhad Manapov; Minglun Li
Journal:  Radiat Oncol       Date:  2014-12-06       Impact factor: 3.481
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.